2208 - ECOG-ACRIN EA4232 Upfront T Cell NHL

Go Back to BMT CTN Protocol Listing

  • Protocol Short Name and Number: EA4232, 2208
  • Protocol Long Name: A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
  • Key Personnel
    • Study Chair: Nora Bennani, MD
    • Protocol Champions:
      • Mehdi Hamadani, MD [BMT CTN]
      • Jakub Svoboda, MD [BMT CTN]
      • Basem M. William, MD [Alliance] 
      • Neil Chua, MD [CCTG]
      • Yazhini Vallatharasu, MD [Community]
      • Brad Kahl, MD [Lymphoma Committee]
      • Mark Hoffman, MD [SWOG-ACRIN]
    • Study Chair liaison: Diana Johnson, rieckenberg.diana@mayo.edu
  • Note: For the ECOG-ACRIN EA4232 / BMT CTN 2208 study, the BMT CTN endorses the study and providing accrual credit. Centers participate via their NCTN group. BMT CTN Centers will receive both NCTN and BMT CTN accrual credits. The protocol may be accessed through the CTSU website: https://www.ctsu.org. For questions about the study and how to participate, contact the ECOG-ACRIN Study Chair, Nora Bennani, bennani.nora@mayo.edu or Study Chair liaison, Diana Johnson, rieckenberg.diana@mayo.edu or the CTSU Help Desk at ctsucontact@westat.com or 1 888 823-5923.